Lipid Nanoparticles for Ocular Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral gene therapy vectors for eye diseases face challenges such as low transfection efficacy, toxicity, immunogenicity, and limitations in genetic material size, necessitating the development of safer and more effective delivery systems.
Innovation Solution
A lipid nanoparticle system comprising a polysaccharide, cationic surfactant, non-ionic surfactant, and optionally a positively charged peptide, which protects genetic material from enzymatic degradation and enhances cell uptake and expression, particularly for retinal degenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-viral vectors are used for gene therapy, then safety is improved, but transfection efficacy deteriorates
Solution Approach 1:
The patent uses composite lipid nanoparticles combining multiple lipid types (cationic, neutral, and fusogenic lipids) with polysaccharides to create a hybrid delivery system that achieves both safety and high transfection efficacy, resolving the contradiction between non-viral safety and viral-level transfection efficiency
Solution Approach 2:
The patent optimizes physical and chemical parameters including nanoparticle size (50-200 nm), zeta potential (+20 to +40 mV), lipid composition ratios, and polysaccharide content to maximize transfection efficacy while maintaining safety, demonstrating how parameter tuning resolves the efficacy-safety tradeoff
2Productivity
If ionic surfactants are added to lipid nanoparticles, then transfection capability is improved, but cell toxicity worsens
Solution Approach 1:
The patent carefully controls the concentration and type of ionic surfactants used in the lipid nanoparticles, optimizing the cationic lipid to neutral lipid ratio and incorporating polysaccharides to shield toxic effects, thereby achieving high transfection capability while minimizing cell toxicity
Solution Approach 2:
The patent introduces polysaccharides as intermediary molecules that mediate between the ionic surfactants and cell membranes, reducing direct toxic interactions while preserving the transfection-enhancing properties of the ionic components
3Stability of the object's composition
If genetic material is protected from enzymatic degradation, then stability is improved, but cell uptake efficiency worsens
Solution Approach 1:
The patent creates lipid nanoparticles with differentiated regions: a protective lipid shell that shields genetic material from enzymatic degradation in circulation, and localized polysaccharide-exposed surfaces that facilitate cell uptake, thereby simultaneously achieving stability and efficiency through spatially differentiated properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle system effectively transfects genetic material into retinal cells, achieving high cell viability and expression of therapeutic genes, such as the RS1 gene for juvenile retinoschisis, while preventing premature degradation and improving transfection levels compared to systems without these components.
Implementation Method 1
The nanoparticle system comprises a cationic surfactant and a polysaccharide, which protect genetic material from enzymatic degradation
Implementation Method 2
facilitating cell uptake and the subsequent release in cell cytoplasm
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to the use of a lipid nanoparticle system, where the nanoparticles comprise a nucleic acid, a lipid component, a cationic surfactant, a non-ionic surfactant, a polysaccharide, and optionally a positively charged peptide for the treatment and prevention of eye diseases.